Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation

PARP inhibitors (PARPi) are the maintenance therapy after first line platinum-based chemotherapy for patients with advanced epithelial ovarian cancer (EOC) with germline and pathogenic somatic BRCA1/2 mutations. However, as with chemotherapy, patients can develop resistance to PARPi. The selective p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Lan, Yin, Rutie, Song, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024533/
https://www.ncbi.nlm.nih.gov/pubmed/36942084
http://dx.doi.org/10.2147/PGPM.S397827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024533/
https://www.ncbi.nlm.nih.gov/pubmed/36942084
http://dx.doi.org/10.2147/PGPM.S397827

Ejemplares similares